Compare INBS & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INBS | SNOA |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.1M |
| IPO Year | 2019 | 2006 |
| Metric | INBS | SNOA |
|---|---|---|
| Price | $1.69 | $1.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.9K | ★ 36.7K |
| Earning Date | 11-11-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.26 |
| EPS | N/A | ★ N/A |
| Revenue | $1,980,484.00 | ★ $19,529,000.00 |
| Revenue This Year | $44.72 | $22.44 |
| Revenue Next Year | $44.26 | $12.73 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.68 |
| 52 Week Low | $0.54 | $0.85 |
| 52 Week High | $24.90 | $4.06 |
| Indicator | INBS | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 42.04 |
| Support Level | $1.52 | $1.03 |
| Resistance Level | $1.92 | $1.29 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 80.95 | 21.05 |
Intelligent Bio Solutions Inc is a medical technology company focused on developing and delivering intelligent, rapid, non-invasive testing and screening solutions. Its current active product is the Intelligent Fingerprinting Platform, consisting of a proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its flagship product, the Intelligent Fingerprinting Drug Screening System, is a two-part system of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The Company operates in APAC, the UK, the Americas, and the rest of the world, with maximum revenue from the United Kingdom.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.